Table 2.
Studies on predictors of cardiac decompensation in patients with cirrhosis post-transjugular intrahepatic portosystemic shunt demographic data
|
Ref.
|
Age (median)
|
Sex (men %)
|
Creatinine (μmol/L)
|
1° cirrhosis aetiology
|
Child-Pugh A/B/C
|
MELD (MELD-Na)
|
TIPS indication
|
HF%
|
Cardiac disease
|
| Ali et al[10] | 58 | 66 | 97.3 (35.4-238.7) | Alcohol (39%) | A: 11%, B: 62%, C: 27% | 15 (7-30) | Ref.A. (50%), V.B. (42%) | 10 | 17% |
| Alla et al[40] | 43 | 79.6 vs 159 | Alcohol | 7 ± 1.21 | 16 ± 5.3 | 22.2 | 66% | ||
| Billey et al[9] | 69 | 79 | 89 ± 53 | Alcohol (74%) | A: 25%, B: 66%, C: 9% | 11.5 ± 4 | Ref.A. (58%), pre-op (23%), V.B. (19%) | 20 | 28% include AS: 10% |
| Filì et al[43] | 54 | 80 | 79.6 vs 97.3 | Viral (73.3% +) | A: 0%, B: 46%, C: 53.3% | 14.3 ± 4 | Ref.A. (100%) | 0 | Excluded |
| Laurenzano et al[39] | 58 | 60 | Alcohol (31%) | 13.1 (9.7-16.7) | Ref.A. (39%), V.B. (33%), H.H. (12%) | 8.8 | Excluded | ||
| Luo et al[44] | Viral (56.4%) | V.B. (80.7%) | 0 | Excluded | |||||
| Modha et al[45] | 58 | 52 | 115 ± 94 | MAFL (35.4%) | A: 20.8%, B: 66.7%, C: 12.5% | 12.0 ± 4.7 | Ref.A. (47.9%), V.B. (31.3%) | 0.9 | 25.90% |
| Nguyen et al[47] | 21 vs 17 | 11.7 | |||||||
| Schneider et al[11] | 59 | 59 | 100 (57.8-135.3) | Alcohol (58.1%) | A: 9.4%, B: 81.2%, C: 9.4% | 12 (10-15) | Ref.A. (82.9%), V.B. (20.5%) | 18 | 39.7% include AS: 8.2% |
| Vanderschueren et al[41] | 63 | 69.8 | 93.73 (64.6-115) | Alcohol (72.6%) | 8 (7.0-9.2) | 12.3 (10.2-16.5) | Ref.A. (58.5%), V.B. (41.5%) | 11.3 | Yes, unclear |
| Venner et al[46] | 64 vs 57 | Ref.A. (50%), V.B. (40%), H.H. (6%) | 44 | ||||||
| Debernardi Venon et al[49] | 59 | 79 | 113.2 ± 5.3 | Alcohol (49%) | A: 0, B: 84%, C: 16% | 13.7 ± 0.55 | Ref.A. (100%) | 3 | Excluded |
| Wade et al[48] | 13.5 vs 17.1 | 14 |
Ref.A.: Refractory ascites; V.B.: Variceal bleeding; H.H.: Hepatic hydrothorax; TIPS: Transjugular intrahepatic portosystemic shunt; MELD: Model for end-stage liver disease; MELD-Na: Model for end-stage liver disease incorporating serum sodium; HF: Heart failure; MAFL: Metabolic-associated fatty liver disease. Studies reporting “excluded” under cardiac disease excluded patients with pre-existing or clinically overt cardiac dysfunction from inclusion. Percentages reflect proportions within each study cohort.